New User:

Forgot your password?

Stock Market & Financial Investment News

News For IMOS;NIHD;CTIC;NTE;EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
09:22 EDTEXELOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PepsiCo (PEP), up 2.6%. ALSO HIGHER: PMC-Sierra (PMCS), up 33.8% after being acquired by Skyworks (SWKS)... Skyworks is up 2.5%... MagneGas (MNGA), up 8.9% after receiving order from a U.S. Army contractor... Exelixis (EXEL), up 5.9% after the phase 3 pivotal trial of cobimetinib met its secondary endpoint... DuPont (DD), up 6.1% after CEO and chair Ellen Kullman retires... Mallinckrodt (MNK), up 3% after providing fiscal 2016 guidance and a business update in a conference call. LOWER: EXACT Sciences (EXAS), down 34.7% after Cologuard included as an alternative screen test under the U.S. Preventive Services Task Force draft guidelines... Illumina (ILMN), down 17.7% after providing third quarter, fourth quarter, and fiscal 2015 guidance... Tesla (TSLA), down 2.5% after Model X forecasts were lowered at Morgan Stanley and the firm cut its price target to $450.
06:24 EDTNIHDNII Holdings initiated with an Underperform at Jefferies
Subscribe for More Information
05:22 EDTEXELExelixis reports phase 3 pivotal trial of cobimetinib met secondary endpoint
Subscribe for More Information
October 2, 2015
17:19 EDTCTICBiotechnology Value Fund reports 5.2% passive stake in CTI BioPharma
October 1, 2015
05:31 EDTCTICCTI BioPharma, Fred Hutchinson Cancer Research Center report research fellowship
Subscribe for More Information
September 25, 2015
18:49 EDTEXELExelixis up 16% after Phase 3 trial of cabozantinib met primary endpoint
In after-hours trading, shares are up 16% to $6.86.
18:16 EDTEXELExelixis says Phase 3 trial of cabozantinib met primary endpoint
Exelixis announced positive results from METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with renal cell carcinoma who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor. In July 2015, Exelixis disclosed that the trial met its primary endpoint, demonstrating a statistically significant increase in progression-free survival for patients in the cabozantinib arm. Principal investigator Toni K. Choueiri, M.D. will present detailed data from the late-breaking METEOR abstract on Saturday, September 26, during the Presidential Session I at the European Cancer Congress 2015, which is being held September 25-29 in Vienna. The METEOR data and an accompanying editorial were also published today in The New England Journal of Medicine.
12:47 EDTEXELExelixis management to meet with William Blair
Meetings to be held in Europe on September 29-30 hosted by William Blair.
07:42 EDTEXELExelixis: CHMP adopts positive opinion for cobimetinib, vemurafenib combination
Subscribe for More Information
07:22 EDTEXELEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
September 24, 2015
16:35 EDTCTICCTI BioPharma announces $15.7M registered direct offering
Subscribe for More Information
September 23, 2015
09:08 EDTCTICCTI BioPharma to submmit NDA for pacrtinib in Q4
CTI BioPharma announced its plan to submit a new drug application to the FDA following a productive pre-NDA meeting for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The company expects to submit the NDA in Q4 and to request accelerated approval for the treatment of patients with intermediate and high-risk myelofibrosis with low platelet counts of less than 50,000 per microliter. Submission of an NDA after a single Phase 3 trial under accelerated approval, instead of waiting to complete two Phase 3 trials, could potentially reduce time to market by up to 14 months.
07:18 EDTEXELExelixis to hold a webcast
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use